Christopher Cutie is the Vice President and Disease Area Leader of Bladder Cancer at The Janssen Pharmaceutical Companies of Johnson & Johnson. He also co – founded Jointpoint and was the chief medical officer at TARIS Bio (acquired by Janssen Oncology).
Chris Cutie/LinkedIn
Oct 21, 2024, 15:05
Chris Cutie on the latest episode of the Uromigos podcast
“In our latest podcast episode, Dr. Chris Cutie of Johnson and Johnson Innovation covers many questions about the gemcitabine-eluting pretzel, like its origin, catheter changes, assessing toxicity, the SunRISe series, and TAR-200 combo agents.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 22:40
Dec 21, 2024, 22:37
Dec 21, 2024, 22:26
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19